These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31978044)

  • 1. Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
    Bowrin K; Briere JB; Fauchier L; Coleman C; Millier A; Toumi M; Clay E; Levy P
    PLoS One; 2020; 15(1):e0225301. PubMed ID: 31978044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
    Dong SJ; Wu B; Zhai SD; Zhang YJ; Chu YB; Gupta P; Li YH
    Clin Ther; 2020 Jan; 42(1):144-156.e1. PubMed ID: 31932080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
    Escobar Cervantes C; Martí-Almor J; Cabeza AIP; Bowrin K; Llorac Moix A; Genís Gironès M; Gasche D; Millier A; Tardu J; Toumi M; Briere JB
    PLoS One; 2022; 17(4):e0266658. PubMed ID: 35443000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
    Mensch A; Stock S; Stollenwerk B; Müller D
    Pharmacoeconomics; 2015 Mar; 33(3):271-83. PubMed ID: 25404426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
    Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
    Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting.
    Morais J; Aguiar C; McLeod E; Chatzitheofilou I; Fonseca Santos I; Pereira S
    Rev Port Cardiol; 2014 Sep; 33(9):535-44. PubMed ID: 25241380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
    de Jong LA; Gout-Zwart JJ; van den Bosch M; Koops M; Postma MJ
    J Med Econ; 2019 Apr; 22(4):306-318. PubMed ID: 30614320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation (NVAF) in Iran.
    Tajik A; Abbasi A; Goudarzi Z; Izadi-Moud A; Varmaghani M
    Clin Cardiol; 2024 Jun; 47(6):e24311. PubMed ID: 38923583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
    Lorenzoni V; Pirri S; Turchetti G
    Clin Drug Investig; 2021 Mar; 41(3):255-267. PubMed ID: 33587284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
    Rudakova AV; Tatarskiĭ BA
    Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
    Kleintjens J; Li X; Simoens S; Thijs V; Goethals M; Rietzschel ER; Asukai Y; Saka Ö; Evers T; Faes P; Vansieleghem S; De Ruyck M
    Pharmacoeconomics; 2013 Oct; 31(10):909-18. PubMed ID: 24030788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
    Monreal-Bosch M; Soulard S; Crespo C; Brand S; Kansal A
    Rev Neurol; 2017 Mar; 64(6):247-256. PubMed ID: 28272725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
    Wang Y; Xie F; Kong MC; Lee LH; Ng HJ; Ko Y
    Cardiovasc Drugs Ther; 2014 Dec; 28(6):575-85. PubMed ID: 25319314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
    Shah A; Shewale A; Hayes CJ; Martin BC
    Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
    Athanasakis K; Karampli E; Tsounis D; Bilitou A; Kyriopoulos J
    Clin Drug Investig; 2015 Nov; 35(11):693-705. PubMed ID: 26385756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.